Versanis Bio
Latest round
- Series A
Last raised
- Aug 2021
Total raised
- $70M
Investors
- 3
About Versanis Bio
Versanis Bio, Inc.Founded in 2020 and headquartered in New York, US, Versanis Bio, Inc. specializes in the development of therapies for obesity and cardiometabolic disorders.Versanis focuses on developing transformative treatments for obesity and cardiometabolic diseases, primarily through a unique approach that targets the activin type II receptors (ActRII) found in fat and muscle cells. The company leverages its understanding of activin biology and incretin biology to create therapies that aim to regulate fat and muscle metabolism. Their research addresses the mechanisms that promote lipid storage, a significant contributor to visceral fat accumulation and obesity, while also inhibiting muscle growth and promoting muscle atrophy. Versanis aims to empower individuals living with obesity by offering solutions that may improve body composition and metabolism while aiding in fat loss.Versanis generates revenue through partnerships and collaborations with healthcare providers and pharmaceutical companies focused on obesity treatment. The transaction structure typically involves licensing agreements or collaborations where Versanis provides its proprietary research and development capabilities, leading to co-developed therapies. Revenue streams are expected to align with the commercialization of their flagship products aimed at obesity and related conditions. The company’s financial model includes milestones based on regulatory approvals and sales performance, as well as potential royalties on product sales.In July 2023, Eli Lilly and Company agreed to acquire Versanis Bio, Inc.925 bn, including upfront payment and future milestone payments. This acquisition will allow Eli Lilly to explore new medicines targeting obesity.S. and European regions, where obesity rates are high. The company is expected to focus on commercializing its innovative therapies in the coming years, aiming to improve healthcare outcomes for individuals suffering from obesity.
Who invested in Versanis Bio
3 investors across 1 round
See all investors in Versanis Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 31, 2021
Amount
$70M
Investors
Questions about Versanis Bio
Who invested in Versanis Bio?
Versanis Bio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Versanis Bio raised?
Versanis Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Versanis Bio last raise money?
Versanis Bio's most recent round on record is a Series A, in Aug 2021.
What does Versanis Bio do?
Versanis Bio is a pharmaceuticals company.
Where is Versanis Bio headquartered?
Versanis Bio is headquartered in New York, US.
Which VCs invest in companies like Versanis Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Versanis Bio's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Versanis Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.